Clinical Applications of Molecular Biomarkers in Prostate Cancer

There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disea...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-06, Vol.12 (6), p.1550
Main Authors: Couñago, Felipe, López-Campos, Fernando, Díaz-Gavela, Ana Aurora, Almagro, Elena, Fenández-Pascual, Esaú, Henríquez, Iván, Lozano, Rebeca, Linares Espinós, Estefanía, Gómez-Iturriaga, Alfonso, de Velasco, Guillermo, Quintana Franco, Luis Miguel, Rodríguez-Melcón, Ignacio, López-Torrecilla, José, Spratt, Daniel E., Guerrero, Luis Leonardo, Martínez-Salamanca, Juan Ignacio, del Cerro, Elia
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the differential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical practice.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12061550